Respiratory syncytial virus (RSV): Potential significant opportunity for effective vaccine

  Pioneering new research into respiratory syncytial virus (RSV) may have overcome the barriers that have impeded the development of an effective vaccine against the deadly virus. RSV is a virus that causes lower respiratory tract infections and is a major cause of childhood morbidity and mortality worldwide. Attempts to develop vaccines against the virus in the 1960s were dogged …

Climate change in vaccine trials: Moving from a one-size-fits-all to a custom fit in operational delivery

Dr Vigdorth has 30 years of drug development research experience in the clinical setting and pharmaceutical and CRO industries. She has led clinical development programs across a range of therapeutic indications with extensive experience in antibiotic, antiviral, vaccine, and antifungal agents.   Dr Vigdorth's experience has developed from multiple perspectives including working in the clinical investigative site setting, multi- national …